Guest Writer
Professor Oliver Gottschalg, head of MJ Hudson’s Fund Performance Analytics team, explains why LPs should focus on whether GPs outperform within their specialist sectors, rather than the wider market.
New fund structures and solvency requirements could lay the groundwork for a wave of emerging managers in the UK, write Adam Palmer and Andrew Poole of governance consultancy ACA Group.
PE firms backing medical device businesses should become familiar with EU regulations that are increasing costs and time-to-market, writes Alison Dennis, Taylor Wessing’s co-head of life sciences and healthcare.
Fundraising in South Korea requires resources, attentiveness and patience, though the country should prove to be fertile ground for the foreseeable future, writes Albert Jun, partner at Monument Group.
Covid-19 precipitated record fund financing activity in 2021, and this upward trajectory has no end in sight, writes Justin Partington, group head of funds at IQ-EQ.
The future of private funds as a longer-term investment option has become a commonplace goal for the market, write Troutman Pepper lawyers Julia Corelli, Stephanie Pindyck Costantino, Patrick Bianchi and Theodore Edwards.
Though increasing in popularity, growth equity investing poses unique issues for sophisticated investors, including the need to research alternative approaches to exit strategies.
There is growing speculation that secondaries trading could surpass primary fundraising, as it has in the public markets, write Rod James and Amy Carroll.
Investor appetite and regulatory imperative are creating demand for net-zero investments and low-cost debt. The private equity sector can benefit from both, say Deniz Harut and Gavin Templeton.
Technology, the rise of entrepreneurs, and globalised business models have transformed the growth equity space in recent years, say Bill Ford and Graves Tompkins of General Atlantic.